From HealthCare Finance, July 11: The Trump Administration has pulled back on its proposal to eliminate safe harbor protections for rebates paid by pharmaceutical manufacturers to PBMs and health plans participating in Medicare and Medicaid. No direct reason was given, but a Reuters source speculated that the administration would instead focus on drug makers. Moody’s credit analysts said the move was positive for health insurers that own large PBMs.